Displaying 501 - 520 of 853
| Active Ingredient | BERACTANT |
| Therapeutic Class | PULMONARTY SURFCTANTS |
| Indications |
Treatment of respiratory distress syndrome in preterm neonates, birth-weight over 700g; prophylaxis of respiratory distress syndrome in preterm neonates less than 32 weeks corrected gestational age. |
| Caution | Intracranial haemorrhage. |
| Dose Range |
Respiratory distress syndrome: 100 mg/kg equivalent to a volume of 4 mL/kg, preferably within 8 hours of birth; dose may be repeated within 48 hours at intervals of at least 6 hours for up to 4 doses. Prophylaxis of respiratory distress syndrome: 100 mg/k |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | BOSENTAN |
| Therapeutic Class | VASODILATING AGENTS MISCELLANEOUS |
| Indications | Pulmonary Hypertension. |
| Caution | Contra-indicated in patients with moderate to severe hepatic impairment, headache, nasopharyngitis, flushing, oedema, hypotension, dizziness, palpitations, gastrointestinal disturbances, pruritus More ... |
| Dose Range | 12 years and older: Initially 62.5 mg twice daily, increased after 4 weeks to a maintenance dose of 125 mg twice daily. Patients with low body weight (below 40kg) 62.5 mg twice daily. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | BUDESONIDE | FORMOTEROL |
| Therapeutic Class | RESPIRATORY AGENTS MISCELLANEOUS |
| Indications | Treatment of asthma. |
| Caution | Beta blockers including eye drops can weaken the effect of the inhaler. Ketoconazole may increase systemic exposure to the budesonide component. Use with caution in patients with cardiovascular disea More ... |
| Dose Range | Adults and Children 12 years and older: 1-2 inhalations once or twice daily . See BDS supply protocols pg. 10. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | BUDESONIDE | FORMOTEROL (120 R) |
| Therapeutic Class | RESPIRATORY AGENTS MISCELLANEOUS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | BUDESONIDE | FORMOTEROL (120) |
| Therapeutic Class | RESPIRATORY AGENTS MISCELLANEOUS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | BUDESONIDE | FORMOTEROL (60) |
| Therapeutic Class | RESPIRATORY AGENTS MISCELLANEOUS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | BUDESONIDE | FORMOTEROL (R) |
| Therapeutic Class | RESPIRATORY AGENTS MISCELLANEOUS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | FLUTICASONE | SALMETEROL |
| Therapeutic Class | RESPIRATORY AGENTS MISCELLANEOUS |
| Indications | Asthma, chronic obstructive pulmonary disease. |
| Caution | Growth suppression, abdominal pain, dyspepsia, candidiasis, osteoporosis, back pain, cataract, glaucoma, chest congestion, hoarseness |
| Dose Range |
Asthma: Adults and Children 12 years and older: 1 inhalation twice daily (50/100, 50/250, 50/500) or 2 inhalations twice daily (25/50, 25/125, 25/250), based on asthma severity . Age 4-11: 1 Inhalation twice daily (50/100) or 2 p uffs tw |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | FLUTICASONE | VILANTEROL |
| Therapeutic Class | RESPIRATORY AGENTS MISCELLANEOUS |
| Indications | Long-term maintenance of airflow obstruction in p atients with chronic obstructive pulmonary disease (COPD). |
| Caution |
Close monitoring for glaucoma and cataracts is warranted. Do not use in combination with an additional LABA because of risk of overdose. Naso-pharyngitis, upper respiratory tract infection, hea More ... |
| Dose Range | One inhalation once daily at the same time each day . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | FORMOTEROL | MOMETASONE |
| Therapeutic Class | RESPIRATORY AGENTS MISCELLANEOUS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | IPRATROPIUM | SALBUTAMOL |
| Therapeutic Class | RESPIRATORY AGENTS MISCELLANEOUS |
| Indications |
Treating moderate-to-severe COPD; it is indicated primarily in patients who fail to resp ond on ipratropium alone. The role of the combination in acute asthma is unclear. |
| Caution | Tachycardia, dry mouth, Bronchitis, upper respiratory tract infections and headache. |
| Dose Range |
Two inhalations four times daily is indicated in chronic obstructive pulmonary disease. In severe acute asthma, ipratropium 0.5mg/salbutamol 2.5mg via nebulizer has been administered. See BDS supply protocols pg. 10. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MOMETASONE | FORMOTEROL |
| Therapeutic Class | RESPIRATORY AGENTS MISCELLANEOUS |
| Indications | As for budesonide/formoterol. |
| Caution | Nasopharyngitis, sinusitis, headache. |
| Dose Range |
Adults and Children 12 years and older: Two inhalations twice daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | UMECLIDINIUM | VILANTEROL |
| Therapeutic Class | RESPIRATORY AGENTS MISCELLANEOUS |
| Indications | Moderate to severe chronic obstructive pulmonary disease (COPD). |
| Caution | As for Vilanterol/Fluticasone; The inhaler should be discarded 6 weeks after opening. |
| Dose Range | One inhalation once daily at the same time each day . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EYE, EAR, NOSE AND THROAT PREPARATIONS |
| Therapeutic Class | EYE, EAR, NOSE AND THROAT PREPARATIONS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | AZELASTINE |
| Therapeutic Class | ANTIALLERGIC AGENTS |
| Indications | Allergic conjunctivitis. |
| Caution | Mild transient eye burning/stinging; bitter taste rep orted. |
| Dose Range |
Seasonal allergic conjunctivitis: Adult and Child over 4 years: Instill twice daily increased if necessary to 4 times daily . Perennial conjunctivitis: Adult and Child over 12 years: Instill twice daily , increased if necessary to 4 times daily ; |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | KETOTIFEN |
| Therapeutic Class | ANTIALLERGIC AGENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | OLOPATADINE |
| Therapeutic Class | ANTIALLERGIC AGENTS |
| Indications | Allergic conjunctivitis. |
| Caution | Headache and stinging or burning of the eye. |
| Dose Range |
Adult and children 3 years and over: 0.1% twice daily ; 0.2% once daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | AZITHROMYCIN |
| Therapeutic Class | EENT ANTIBACTERIALS |
| Indications |
Trachomatous conjunctivitis caused by Chlamydia trachomatis Purulent bacterial conjunctivitis. |
| Caution | Blurred vision; ocular burning; ocular discomfort; ocular pruritus . |
| Dose Range |
Twice daily for 3 days, review if no improvement after 3 days of treatment. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | CHLORAMPHENICOL |
| Therapeutic Class | EENT ANTIBACTERIALS |
| Indications | Bacterial infection in otitis externa. |
| Caution | Avoid prolong use. |
| Dose Range | 2-3 drops 3 times daily . Apply ointment 2-3 times daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | CIPROFLOXACIN |
| Therapeutic Class | EENT ANTIBACTERIALS |
| Indications | Corneal ulcer, superficial bacterial infections caused by susceptible strains. |
| Caution |
Corneal deposits (reversible after completion of treatment); ocular discomfort; ocular hyperaemia; taste disturbance. Local discomfort, pain, or pruritus have occurred after use of ear drops. |
| Dose Range |
Drop: 4 times a day, Ointment: 1.25 centimetres 3 times a day for 2 days, then apply 1.25 centimetres twice daily for 5 days. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |